ArticleEpilepsia2026
New onset refractory status epilepticus (NORSE) versus refractory status epilepticus not meeting NORSE criteria: A comparative clinical and electroencephalography-based study.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical outcomes and unmet therapeutic needs in new-onset refractory status epilepticus: evidence from a retrospective cohort.Neurological research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveNew onset refractory status epilepticus (NORSE) is a rare, severe presentation of refractory status epilepticus (RSE), with approximately half of cases cryptogenic NORSE (c-NORSE). We compared electroencephalographic (EEG) findings alongside clinical features between NORSE and RSE not meeting NORSE criteria to better understand outcomes and prognostication.
methodsThis retrospective cohort study analyzed 81 RSE patients admitted to the intensive therapy unit (ITU) at the National Hospital for Neurology and Neurosurgery and University College London Hospital (2007-2023). Patients were categorized as RSE not meeting NORSE criteria (n = 52) or NORSE (n = 29). EEG features, treatment, and outcomes (ITU stay, mortality, cognitive outcome, and antiseizure medication [ASM] use), were evaluated.
resultsOf 29 NORSE patients (15 c-NORSE, 51.7%; 14 etiology-identified NORSE, 48.3%), autoimmune (20.7%) and infectious (17.2%) etiologies were most prevalent. Six-month mortality was higher in c-NORSE than etiology-identified NORSE (20.0% vs. 7.1%), but similar between NORSE and RSE not meeting NORSE criteria (13.8% vs. 21.1%). EEG analysis revealed longer seizure duration (mean = 243.38 vs. 51.67 s, p < .001), a tendency to higher seizure frequency (.013 vs. .009 seizures/min, p = .076), and increased presence of generalized periodic epileptiform discharges and stimulus-induced rhythmic, periodic, or ictal discharges in NORSE than RSE not meeting NORSE criteria. Across all patients, higher initial seizure burden correlated with longer ITU admissions and worse outcomes. Compared with RSE not meeting NORSE criteria, NORSE patients had longer ITU stays (median = 51 vs. 11 days, p < .001), more ASMs (mean = 3.91 vs. 2.00, p = .031), greater sedative use (mean = 2.17 vs. 1.00, p < .001), and more frequent cognitive impairment at discharge (88.9% vs. 62.2%, p = .037). SIGNIFICANCE: NORSE, particularly c-NORSE, tends to follow a more severe course than RSE not meeting NORSE criteria, with more severe background EEG features including the initial EEG, greater seizure burden, longer ITU stays, and increased incidence of cognitive impairment at discharge. Six-month mortality was similar, implying additional contributing factors to mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.